GSK
4 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community

GlaxoSmithKline (GSK) plc today launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma co... Read More
GSK
4 years ago ⋅ English ⋅ 1 min read
Newsroom
GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&D

GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&DGSK today announced that Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D... Read More
GSK
4 years ago ⋅ English ⋅ 9 min read
Newsroom
GSK showcases progress from the DREAMM clinical trial programme in multiple myeloma at the 2021 ASH Annual Meeting

For media and Investors onlyData demonstrate potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in patients with newly diagnosed and relapse... Read More
GSK
4 years ago ⋅ English ⋅ 13 min read
Newsroom
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment

For media and investors onlyIssued: London UK and San Francisco US- US government contracts for approximately $1 billion(USD) now in place to purchase sotrovimab, further expanding acce... Read More
GSK
4 years ago ⋅ English ⋅ 8 min read
Newsroom
European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases

For media and investors only- Approval for the first targeted treatment for eosinophilic granulomatosis with polyangiitis and the first anti-IL-5 biologic treatment for patients with hy... Read More
GSK
4 years ago ⋅ English ⋅ 12 min read
Newsroom
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

For media and investors onlyIssued: London UK and San Francisco US- COMET-TAIL Phase III data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered s... Read More